Centre of Research Excellence to Improve the QuALIty of SurVival in Gynaecological Cancer PatiEnts (ALIVE WELL)

feMMe

Endometrial cancer affects more than 3,000 women in Australia every year. Standard treatment is by hysterectomy. The feMMe clinical trial treated women with endometrial cancer less-invasively through the use of the Mirena, an intra-uterine device. The results revealed the fertility-sparing treatment is well tolerated and leads to complete pathologic response in up to 60% of women. Unfortunately, we cannot predict yet who will benefit from this treatment. If we can determine who will respond, clinicians could specifically offer this treatment to women who will likely benefit. The feMMe Molecular study will use blood and tissue samples collected as part of the feMMe trial, to identify predictive biomarkers of LNG-IUD response that indicate whether a patient will or will not benefit from this new treatment. Using the findings, we will develop a personalised decision tool that clinicians and patients can use to decide on the best treatment for them.

SATELLITE

The SATELLITE study focuses on evaluating the effectiveness and safety of Dostarlimab, a new immunotherapy treatment for patients with early-stage endometrial cancer. With its favourable pharmacokinetic and safety profile, dostarlimab provides a potential active and tolerable surgery-sparing strategy. This Phase 2b clinical trial will see 10 women participating in the treatment regimen for a 12 month period. If successful, this treatment could be approved for wider use, providing more women with a non-surgical alternative to treat early-stage endometrial cancer.

Semaglutide Study

The majority of women who successfully completed uterus-preserving treatment for endometrial cancer (feMMe trial) may not fall pregnant post-treatment due to underlying medical issues. Semaglutide is registered in Australia as an adjunct diabetes mellitus treatment and evidence suggests it is effective in the treatment of polycystic ovary syndrome. The Semaglutide study will provide 30 women an opportunity to receive the treatment over a 12 month period and follow them for a further 24 month period to determine feasibility and effectiveness.

ENDO-3

Clinical management guidelines for early-stage endometrial cancer prescribes surgical staging through a lymph node dissection (LND). To date, no randomised clinical trial has shown a patient benefit for LND versus no-LND. Lymphoedema is a burdensome and long-term side effect of LND as part of cancer treatment. ENDO-3 is a national and international Phase 3 randomised clinical trial which aims to determine if there is value to retaining the LND procedure. The results of this study will inform clinical practice management guidelines and influence health policy. We aim to enrol 760 patients, with the key outcome to improve the quality of life of women after surgical treatment of endometrial cancer.

Pre-ANVU & ANVU

Around 400 Australian women are diagnosed with vulvar cancer every year and an estimated 2,500 survivors are currently living with debilitating and long-term side effects following treatment. Standard treatment involves the removal of the groin lymph nodes, which puts patients at a high risk of lymphoedema. The ANVU trial aims to reduce the risk of debilitating morbidity from vulvar cancer treatment, without compromising survival. Driven by patient concerns about treatment and need for other options, Pre-ANVU was a feasibility pilot cohort study to determine the diagnostic accuracy of a non-invasive groin ultrasound in predicting the presence of cancer in the groin lymph nodes. ANVU will be a Phase 2 national and international clinical trial, recruiting 240 women and assessing patient health outcomes related to quality of life.

ECHO

Ovarian cancer is the most common cause of gynaecological cancer death. Side effects from the disease and its associated treatments are common, contributing to dose reductions or delays in treatment, as well as leading to declines in quality of life, high morbidity and mortality. The ECHO trial is a Phase 3 Randomised Clinical Trial assessing whether exercise during chemotherapy can improve physical wellbeing, adherence to chemotherapy and treatment outcomes for 500 women with ovarian cancer. We will use the ECHO data to provide new insights into the mechanisms and mediators of exercise-induced effects on cancer biology and progression, and will produce the implementation evidence and tools required for equitable system change in ovarian cancer care.

ACUMEN

Exercise reduces the detrimental side effects of cancer treatments. However, most women recovering from gynaecological cancer have limited access to the support that would help them safely integrate exercise into their daily lives. We have recruited 328 women, with a randomised group completing a personalised exercise program over a 12 week period. The ACUMEN trial aims to improve women’s overall wellbeing and important aspects of health after treatment for gynaecological cancer, and to demonstrate the benefits of exercise as cost-effective ‘usual care’ after treatment.

RECENTRE

Almost 27,000 Australian women are diagnosed with breast and gynaecological cancer every year. Many survive into old age after successful treatment. But survival does not mean women automatically return to good health. The RECENTRE trial will see 800 women receiving whole of lifestyle intervention to improve quality of life and health following cancer treatment. 

Chief Investigators

	Professor Andreas Obermair Project Lead The University of Queensland   NHMRC Leadership Fellow, The University of Queensland Gynaecological oncologist
	Dr Eva Baxter Translational biomarker research lead The University of Queensland   Research Fellow, The University of Queensland
	Professor Beverley Vollenhoven Reproductive medicine lead Monash University   Carl Wood Professor Obstetrics & Gynaecology, Monash University Director Gynaecology, Monash Health Reproductive Endocrinologist and Infertility Specialist, Monash IVF
	Professor Sandra Hayes Epidemiology and exercise oncology lead Cancer Council Queensland   Professor of Epidemiology and Exercise Oncology Science, Griffith University.
	Professor Sandie McCarthy Recovery care lead and EMCR mentor Griffith University   Professor of Clinical Nursing, The University of Queensland and Mater Research Institute. Dean Research, Griffith University.
	Professor Linda Mileshkin Medical oncology lead Peter MacCallum Cancer Centre   Director Medical Oncology, Peter MacCallum Cancer Centre. Australia New Zealand Gynaecological Oncology Group (ANZGOG) endometrial cancer initiative (EDEN) Chair.
	Professor Monika Janda Behavioural science lead and consumer liaison officer The University of Queensland   Professor in Behavioural Science and Health Psychologist, The University of Queensland
	Dr Kristy Robledo Statistical leadership The University of Sydney   Research Fellow (biostatistics), NHMRC Clinical Trials Centre, and NHMRC Emerging Leader Fellow, The University of Sydney
	Professor Haitham Tuffaha Economic evaluation health interventions The University of Queensland   Interim Director of the Centre for the Business and Economics of Health, The University of Queensland
	Professor Val Gebski Biostatistician and methods training lead The University of Sydney   Emeritus Professor in Biostatistics, NHMRC Clinical Trials Centre, The University of Sydney

Associate Investigators

See our research news

Queensland Centre for Gynacological Cancer Research

Events

2025 Gynaecological Cancer Patient Symposium

Date: 30 August 2025

Time: 9:30 - 1:30pm

Venue: Victoria Park, Alabaster Room, 509 Herston Road, Herston

Join us for an enlightening and supportive event designed to connect, reflect, and learn about the latest advancements in gynaecological cancer research. This symposium is a fantastic opportunity for patients, families, and their support teams to gain insights from leading experts and stay informed about ‘hot topics’ in the field.

Find out more and register or the session